자동 인슐린 투여 시스템 시장 규모, 점유율 및 동향 분석 보고서 : 제품 유형별, 당뇨병 유형별, 연령대별, 최종 용도별, 지역별 및 부문별 전망(2026-2033년)

Automated Insulin Delivery Systems Market Summary

The global automated insulin delivery systems market size was valued at USD 5.7 billion in 2025 and is projected to grow from USD 6.5 billion in 2026 to USD 18.8 billion by 2033, at a CAGR of 16.3% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 40.7% in 2025. The automated insulin delivery (AID) systems combine an insulin pump, continuous glucose monitoring (CGM), and a software algorithm that uses glucose information to automatically adjust insulin delivery. The growing diabetes burden is creating a large underlying need for effective insulin-management solutions.

The International Diabetes Federation estimates that 589 million adults aged 20-79 years were living with diabetes globally in 2024, with the number projected to rise substantially over the coming decades. This expanding patient population, particularly people requiring intensive insulin therapy, provides a growing base of potential users for advanced insulin-delivery technologies.

A major factor supporting market growth is the increasing adoption of CGM and integrated diabetes technologies. CGM provides the continuous glucose information required for AID algorithms to automatically adjust insulin delivery, making CGM integration an important foundation for AID adoption. The American Diabetes Association's 2026 Standards of Care recommends CGM for people with diabetes using insulin and recognizes AID systems as a major component of modern diabetes technology. The guideline describes AID systems as technologies that use CGM-informed algorithms to modulate insulin delivery, demonstrating the increasing role of integrated pump-CGM systems in routine diabetes management. As CGM becomes more widely adopted and device interoperability improves, patients and healthcare professionals have greater access to integrated solutions capable of providing automated insulin adjustments.

Growing clinical evidence and expanding use of AID beyond type 1 diabetes are also strengthening market demand. Historically, AID systems were primarily associated with type 1 diabetes, but recent clinical studies have demonstrated benefits among insulin-treated people with type 2 diabetes. In a 2025 randomized clinical trial published in the New England Journal of Medicine, adults with insulin-treated type 2 diabetes who received AID experienced a greater reduction in HbA1c than those continuing their previous insulin-delivery method while using CGM. Another 2025 clinical study involving 305 adults with type 2 diabetes reported a reduction in average HbA1c from 8.2% to 7.4% after 13 weeks of AID use. These findings support the expansion of AID technology into a substantially broader insulin-treated population and strengthen the clinical rationale for adoption.

Global Automated Insulin Delivery Systems Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global automated insulin delivery systems market report based on product, diabetes type, age group, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Predictive Low Glucose Suspend (PLGS) System
• Fully Closed Loop (FCL) System
• Advanced Hybrid Closed Loop (AHCL) System
• Diabetes Type Outlook (Revenue, USD Million, 2021 - 2033)
• Type 1 Diabetes
• Type 2 Diabetes
• Age Group Outlook (Revenue, USD Million, 2021 - 2033)
• Pediatric
• Adult & Geriatric
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals and Clinics
• Homecare Settings
• Others
• Region Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • China
  • Japan
  • South Korea
  • Thailand
  • Australia
  • India
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Diabetes Type
  • 1.2.3. Age Group
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Diabetes Type outlook
  • 2.2.3. Age Group outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Automated Insulin Delivery Systems Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Automated Insulin Delivery Systems Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Automated Insulin Delivery Systems Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Automated Insulin Delivery Systems Market: Product Movement Analysis
• 4.3. Automated Insulin Delivery Systems Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Predictive Low Glucose Suspend (PLGS) System
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Fully Closed Loop (FCL) System
  • 4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Advanced Hybrid Closed Loop (AHCL) System
  • 4.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Automated Insulin Delivery Systems Market: Diabetes Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Automated Insulin Delivery Systems Market: Diabetes Type Movement Analysis
• 5.3. Automated Insulin Delivery Systems Market by Diabetes Type Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Type 1 Diabetes
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Type 2 Diabetes
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Automated Insulin Delivery Systems Market: Age Group Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Automated Insulin Delivery Systems Market: Age Group Movement Analysis
• 6.3. Automated Insulin Delivery Systems Market by Age Group Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Pediatric
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Adult & Geriatric
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Automated Insulin Delivery Systems Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Automated Insulin Delivery Systems Market: End Use Movement Analysis
• 7.3. Automated Insulin Delivery Systems Market by End Use Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. Hospitals and Clinics
  • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Homecare Settings
  • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Automated Insulin Delivery Systems Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Regional Automated Insulin Delivery Systems Market Movement Analysis
• 8.3. Automated Insulin Delivery Systems Market: Regional Estimates & Trend Analysis by Product & Diabetes Type
• 8.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 8.5. North America
  • 8.5.1. North America Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. U.S.
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement scenario
    • 8.5.2.5. U.S. Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement scenario
    • 8.5.3.5. Canada Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement scenario
    • 8.5.4.5. Mexico Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Europe
  • 8.5.6. Europe Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. UK
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement scenario
    • 8.5.7.5. UK Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Germany
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement scenario
    • 8.5.8.5. Germany Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. France
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement scenario
    • 8.5.9.5. France Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.10. Italy
    • 8.5.10.1. Key Country Dynamics
    • 8.5.10.2. Competitive Scenario
    • 8.5.10.3. Regulatory Framework
    • 8.5.10.4. Reimbursement scenario
    • 8.5.10.5. Italy Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.11. Spain
    • 8.5.11.1. Key Country Dynamics
    • 8.5.11.2. Competitive Scenario
    • 8.5.11.3. Regulatory Framework
    • 8.5.11.4. Reimbursement scenario
    • 8.5.11.5. Spain Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.12. Denmark
    • 8.5.12.1. Key Country Dynamics
    • 8.5.12.2. Competitive Scenario
    • 8.5.12.3. Regulatory Framework
    • 8.5.12.4. Reimbursement scenario
    • 8.5.12.5. Denmark Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.13. Sweden
    • 8.5.13.1. Key Country Dynamics
    • 8.5.13.2. Competitive Scenario
    • 8.5.13.3. Regulatory Framework
    • 8.5.13.4. Reimbursement scenario
    • 8.5.13.5. Sweden Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.14. Norway
    • 8.5.14.1. Key Country Dynamics
    • 8.5.14.2. Competitive Scenario
    • 8.5.14.3. Regulatory Framework
    • 8.5.14.4. Reimbursement scenario
    • 8.5.14.5. Norway Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement scenario
    • 8.6.2.5. Japan Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement scenario
    • 8.6.3.5. China Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement scenario
    • 8.6.4.5. India Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement scenario
    • 8.6.5.5. South Korea Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement scenario
    • 8.6.6.5. Australia Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement scenario
    • 8.6.7.5. Thailand Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement scenario
    • 8.7.2.5. Brazil Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement scenario
    • 8.7.3.5. Argentina Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Middle East & Africa
  • 8.8.1. Middle East & Africa Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement scenario
    • 8.8.2.5. South Africa Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement scenario
    • 8.8.3.5. Saudi Arabia Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement scenario
    • 8.8.4.5. UAE Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement scenario
    • 8.8.5.5. Kuwait Automated Insulin Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Key Company Profiles
  • 9.2.1. Medtronic plc
    • 9.2.1.1. Company Overview
    • 9.2.1.2. Financial Performance
    • 9.2.1.3. Product Benchmarking
    • 9.2.1.4. Strategic Initiatives
  • 9.2.2. Tandem Diabetes Care
    • 9.2.2.1. Company Overview
    • 9.2.2.2. Financial Performance
    • 9.2.2.3. Product Benchmarking
    • 9.2.2.4. Strategic Initiatives
  • 9.2.3. Insulet Corporation
    • 9.2.3.1. Company Overview
    • 9.2.3.2. Financial Performance
    • 9.2.3.3. Product Benchmarking
    • 9.2.3.4. Strategic Initiatives
  • 9.2.4. Ypsomed
    • 9.2.4.1. Company Overview
    • 9.2.4.2. Financial Performance
    • 9.2.4.3. Product Benchmarking
    • 9.2.4.4. Strategic Initiatives
  • 9.2.5. Nikkiso Co., Ltd.
    • 9.2.5.1. Company Overview
    • 9.2.5.2. Financial Performance
    • 9.2.5.3. Product Benchmarking
    • 9.2.5.4. Strategic Initiatives
  • 9.2.6. Beta Bionics, Inc.
    • 9.2.6.1. Company Overview
    • 9.2.6.2. Financial Performance
    • 9.2.6.3. Product Benchmarking
    • 9.2.6.4. Strategic Initiatives
  • 9.2.7. Diabeloop
    • 9.2.7.1. Company Overview
    • 9.2.7.2. Financial Performance
    • 9.2.7.3. Product Benchmarking
    • 9.2.7.4. Strategic Initiatives
  • 9.2.8. Medtrum GmbH
    • 9.2.8.1. Company Overview
    • 9.2.8.2. Financial Performance
    • 9.2.8.3. Product Benchmarking
    • 9.2.8.4. Strategic Initiatives
  • 9.2.9. CamDiab
    • 9.2.9.1. Company Overview
    • 9.2.9.2. Financial Performance
    • 9.2.9.3. Product Benchmarking
    • 9.2.9.4. Strategic Initiatives
  • 9.2.10. Sequel Med Tech, LLC
    • 9.2.10.1. Company Overview
    • 9.2.10.2. Financial Performance
    • 9.2.10.3. Product Benchmarking
    • 9.2.10.4. Strategic Initiatives